TABLE 1.
Demographic and Clinical Characteristics
| Total cohort (n=71) | Uremia (n=17) | No uremia (n=54) | P value | |
|---|---|---|---|---|
| Age (years) | 63.4 ± 15.9 | 63.8 ± 12.3 | 63.3 ± 17.0 | 0.89 |
| Male gender n (%) | 32 (54.9) | 5 (29.6) | 27 (50) | 0.22 |
| Caucasian n (%) | 42 (59.2) | 5 (29.4) | 37 (68.5) | 0.01 |
| Diabetes n (%) | 33 (46.4) | 12 (70.5) | 21 (38.9) | 0.04 |
| Hypertension n (%) | 52 (73.2) | 12 (70.5) | 40 (74.1) | 0.76 |
| Coronary artery disease n (%) | 38 (53.5) | 12 (70.5) | 16 (29.6) | 0.01 |
| Hyperlipidemia n (%) | 35 (49.2) | 10 (58.8) | 25 (46.3) | 0.53 |
| Current or former smoker n (%) | 34 (47.9) | 9 (52.9) | 25 (46.2) | 0.84 |
| Total cholesterol (mg/dL) | 158.0 ± 44.5 | 134.5 (128.8–164.8) | 163.4 ± 43.8 | 0.14 |
| HDL (mg/dL) | 47.3 ± 14.0 | 45.7 ± 12.1 | 48.1 ± 15.0 | 0.47 |
| LDL (mg/dL) | 85.4 ± 40.0 | 75.9 ± 46.3 | 90.3 ± 36.4 | 0.11 |
| Triglycerides (mg/dL) | 125.2 ± 57.7 | 126.0 ± 48.1 | 124.8 ± 62.7 | 0.60 |
| HgbA1c (%) | 6.4 (5.7–7.7) | 6.4 ± 1.6 | 6.9 (6.2–8.4) | 0.04 |
| HgbA1C (%) in diabetics only | 6.9 (5.9–9.1) | 8.0±1.9 | 5.9 (5.3–7.2) | 0.03 |
| BMI (kg/m2) | 29.6 ± 7.6 | 26.9 ± 5.9 | 29.1 ± 8.2 | 0.25 |
| BMI ≥ 30 n (%) | 27 (38.0) | 6 (35.2) | 21 (38.9) | 0.79 |
| ASA n (%) | 43 (60.6) | 11 (64.7) | 32 (59.3) | 0.91 |
| Beta blocker n (%) | 38 (53.5) | 15 (88.2) | 23 (42.6) | 0.01 |
| Statin n (%) | 40 (56.3) | 11 (64.7) | 29 (53.7) | 0.93 |
| Metformin n (%) | 7 (9.9) | 0 | 7 (13.0) | 0.18 |
| Glitazone n (%) | 0 | 0 | 0 | 0 |
| ACE inhibitor and/or ARB n (%) | 30 (42.2) | 6 (35.3) | 24 (44.4) | 0.58 |